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Excessive weight gain following therapy for
hyperthyroidism — a major problem
One of the most characteristic presenting features of
hyperthyroidism is weight loss, despite an increased appetite.
This phenomenon is easily understandable, as hyperthyroidism
is accompanied by a rise in metabolic rate, energy expenditure
and thermogenesis which is clearly not matched by an
increased appetite and caloric intake in the vast majority of
patients.  Consequently a decrease in adipose tissue and
muscle results.  (Curiously a small proportion of hyperthyroid
patients, fewer than 10%, present with weight gain owing to an
increased appetite that exceeds the rise in metabolic rate.1)
Intuitively, one might assume that restoration of thyroid
hormone levels to normal would result in the return of weight
to premorbid levels.  Unfortunately, the insidious presentation
of hyperthyroidism, and inaccurate recall by patients,
complicate a true assessment of premorbid weight.
Nevertheless, just over half of the respondents to a
questionnaire sent to women treated for hyperthyroidism
reported experiencing a weight problem over a mean follow-up
period of 4 years. 2 Furthermore, numerous reports, including
that by Brunova et al.3 in this issue of S A M J (p. 529), corro b o rate
the notion that weight gain following therapy for
hyperthyroidism is frequently excessive.  A mean increase in
weight of between 1.55 and 16.4 kg has been reported
following anti-thyroid therapy.2-6 Indeed, patients attending our
clinic have become aware of this phenomenon, as they
commonly express concern that treating their hyperthyroidism
will lead to excessive weight gain.
Brunova et al. report a retrospective analysis of 160 patients
who were treated for hyperthyroidism; 147 were treated with
radioactive iodine, 3 underwent thyroidectomy and the
remainder received carbimazole. Hypothyroidism ensued in
86.7% of the former two groups and was treated with
thyroxine.3 As the premorbid weight could not be ascertained
accurately, the baseline weight was taken as the weight at
presentation.  Weight gain was noted for 24 months, but it
stabilised thereafter.  The median weight gain found was 5 kg,
6 months after definitive therapy, 9 kg after 12 months and 12
kg after 24 months.  Importantly, 29% of their cohort were
overweight at presentation (body mass index (BMI) > 25
kg/m2) and 19.3% were obese (BMI > 30 kg/m2).  Two years
after treatment, 51.3% had become obese, representing a 32%
increase in the prevalence of obesity.
Notable predictors of weight gain in studies of patients
treated for hyperthyroidism have included a history of weight
loss prior to diagnosis, pre-existing obesity, a diagnosis of
Graves’ disease and the development of hypothyroidism, even
transiently.5 In contrast, patient age, sex and mode of therapy
have not been predictive.2,5 Brunova et al. described similar
major factors associated with increased weight gain, i.e. the
diagnosis of Graves’ disease, need for thyroxine therapy and
poor control of thyroid function on such replacement therapy.3
Yet the extent of weight gain and the rise in the prevalence of
obesity was greater than reported by others.  For example, Dale
and colleagues, who also did not know patients’ premorbid
weight, described a mean weight gain of 5.4 ± 0.5 kg and an
18.5% prevalence of obesity.5 Possible explanations for these
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differences are the significantly greater proportion of patients
who were obese at baseline in the local study, which represents
a major risk factor for further weight gain and a higher rate of
non-compliance with thyroxine replacement.  
A number of mechanisms have been proposed for the weight
gain following treatment of hyperthyroidism.  Although it has
been demonstrated that food energy intake decreases once
hyperthyroidism is treated, this reduction may be insufficient
relative to the fall in metabolic rate, leading to the
overshooting of the premorbid weight.4 Others have suggested
that there is a long-term disturbance in neurochemical
regulation of appetite and weight after hyperthyroidism. 7
Recently, Tigas and colleagues8 suggested that circulating tri-
iodothyronine (T3) may be inadequate, when providing
thyroxine (T4) alone in the form of thyroxine in patients
rendered hypothyroid following treatment of
hyperthyroidism.8 However, more research is required before
any recommendations can be made that  T3 be replaced
together with T4 rather than the current practice of T4
replacement alone.
Obesity has become a major public health problem in both
developed and developing countries, and it is now recognised
as a disease with morbidity comparable to that of
hypertension.9 As clinicians we should be creating an
awareness of the importance of maintaining a healthy weight
in all our patients, but particularly in those most at risk of
weight gain and obesity.  Healthy food choices and
performance of regular exercise should be stressed for all.  In
order to lessen the risk of excessive weight gain among
patients treated for hyperthyroidism, we should ensure that
hyperthyroid patients receive appropriate advice to restrict
energy intake once on treatment and thus reduce a possible
contributor to the ranks of the obese, a method proven to be of
benefit.10 In addition, replacement therapy with thyroxine
should be commenced timeously when hypothyroidism arises,
and finally thyroid hormone levels (thyroid-stimulating
hormone and T4) should be meticulously maintained within
the normal range.
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